Colorectal Cancer; Novel Approaches in Chimeric Antigen Receptors (CAR) -T cell.

IF 0.8 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Mahyar Haki, Mohammad Darvishi
{"title":"Colorectal Cancer; Novel Approaches in Chimeric Antigen Receptors (CAR) -T cell.","authors":"Mahyar Haki, Mohammad Darvishi","doi":"10.22088/IJMCM.BUMS.14.2.777","DOIUrl":null,"url":null,"abstract":"<p><p>Colorectal cancer (CRC) is a popular type of cancer, characterized by high mortality and a notable impression on the well-being of individuals. The success of adoptive chimeric antigen receptor T (CAR-T) cell therapy in treating hematological malignancies has been remarkable in recent years; however, its application in solid tumors like CRC has many challenges. These obstacles encompass the immunosuppressive microenvironment of the tumor, the insufficient targeting of CAR-T cells, the limited lifespan of CAR-T cells within the body, and the constrained capacity for proliferation. Additionally, CAR-T cells face hurdles in effectively infiltrating the tumor site, which further complicates treatment outcomes. Diverse innovative strategies have been suggested to surmount these barriers in the context of CRC. This comprehensive review endeavors to meticulously elucidate an exhaustive and detailed evaluation of the prevailing and contemporary landscape concerning CAR-T cell therapy as it pertains to the intricate management of CRC, while simultaneously offering a thorough indication of the various risk factors and the associated prevalence that are intricately linked with the manifestation and progression of CRC.</p>","PeriodicalId":14152,"journal":{"name":"International Journal of Molecular and Cellular Medicine","volume":"14 2","pages":"777-792"},"PeriodicalIF":0.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12321304/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Molecular and Cellular Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22088/IJMCM.BUMS.14.2.777","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Colorectal cancer (CRC) is a popular type of cancer, characterized by high mortality and a notable impression on the well-being of individuals. The success of adoptive chimeric antigen receptor T (CAR-T) cell therapy in treating hematological malignancies has been remarkable in recent years; however, its application in solid tumors like CRC has many challenges. These obstacles encompass the immunosuppressive microenvironment of the tumor, the insufficient targeting of CAR-T cells, the limited lifespan of CAR-T cells within the body, and the constrained capacity for proliferation. Additionally, CAR-T cells face hurdles in effectively infiltrating the tumor site, which further complicates treatment outcomes. Diverse innovative strategies have been suggested to surmount these barriers in the context of CRC. This comprehensive review endeavors to meticulously elucidate an exhaustive and detailed evaluation of the prevailing and contemporary landscape concerning CAR-T cell therapy as it pertains to the intricate management of CRC, while simultaneously offering a thorough indication of the various risk factors and the associated prevalence that are intricately linked with the manifestation and progression of CRC.

Abstract Image

Abstract Image

Abstract Image

结直肠癌;嵌合抗原受体(CAR) -T细胞的新方法。
结直肠癌(CRC)是一种常见的癌症类型,其特点是死亡率高,对个体的健康有显著的影响。近年来,过继性嵌合抗原受体T (CAR-T)细胞治疗血液系统恶性肿瘤取得了显著的成功;然而,其在CRC等实体肿瘤中的应用仍面临诸多挑战。这些障碍包括肿瘤的免疫抑制微环境、CAR-T细胞的靶向性不足、CAR-T细胞在体内的寿命有限以及增殖能力受限。此外,CAR-T细胞在有效浸润肿瘤部位方面面临障碍,这进一步使治疗结果复杂化。人们提出了多种创新策略来克服CRC背景下的这些障碍。这篇全面的综述努力细致地阐明了关于CAR-T细胞治疗的当前和当代景观的详尽和详细的评估,因为它涉及到CRC的复杂管理,同时提供了与CRC的表现和进展复杂相关的各种风险因素和相关患病率的全面指示。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.60
自引率
0.00%
发文量
0
期刊介绍: The International Journal of Molecular and Cellular Medicine (IJMCM) is a peer-reviewed, quarterly publication of Cellular and Molecular Biology Research Center (CMBRC), Babol University of Medical Sciences, Babol, Iran. The journal covers all cellular & molecular biology and medicine disciplines such as the genetic basis of disease, biomarker discovery in diagnosis and treatment, genomics and proteomics, bioinformatics, computer applications in human biology, stem cells and tissue engineering, medical biotechnology, nanomedicine, cellular processes related to growth, death and survival, clinical biochemistry, molecular & cellular immunology, molecular and cellular aspects of infectious disease and cancer research. IJMCM is a free access journal. All open access articles published in IJMCM are distributed under the terms of the Creative Commons Attribution CC BY. The journal doesn''t have any submission and article processing charges (APCs).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信